Development of a psoriasis-like eruption during treatment with mepolizumab: A case report

Mepolizumab is effective for treating eosinophilic granulomatosis with polyangiitis (EGPA), severe eosinophilic asthma (SEA), and chronic rhinosinusitis with nasal polyps (CRSwNP), but unexpected adverse events associated with anti-interleukin-5 (IL-5) monoclonal antibodies have not yet been fully characterized. Herein, we report the case of a 56-year-old woman who developed a psoriasis-like eruption ~18 months after starting subcutaneous mepolizumab (300 mg every 4 weeks) for EGPA, SEA, and CRSwNP. She had no personal or family history of psoriasis or atopic dermatitis. Small punctate erythematous lesions first appeared on the back, before gradually spreading to the trunk and extremities. Skin biopsy showed neutrophilic infiltration within the stratum corneum, focal hypogranulosis, dilated tortuous capillaries, and increased mitotic activity in the basal layer. Prominent regular elongation of the rete ridges was not evident. The overall clinicopathological findings supported a diagnosis of a psoriasis-like eruption, with no eosinophils being identified in either the epidermis or dermis. Topical treatment with calcipotriol and betamethasone, while mepolizumab was continued at the same dose, produced only temporary improvement followed by recurrence. The eruption improved following temporary mepolizumab discontinuation, but the patient’s asthma exacerbations recurred. The mepolizumab dose was therefore reduced to 100 mg every 4 weeks, and a potent topical corticosteroid was added. The eruption resolved within 3 months thereafter, without recurrence, and control of EGPA, SEA, and CRSwNP was maintained. Although the psoriasis-like eruption improved after mepolizumab dose reduction, the concurrent topical treatment intensification means this improvement cannot be attributed to the dose reduction alone.

Authors

Institutions

Publication Details

Journal
Modern Rheumatology Case Reports
Published
2026-11-21
DOI
https://doi.org/10.1093/mrcr/rxag111
Primary Topic
Drug-Induced Adverse Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development of a psoriasis-like eruption during treatment with mepolizumab: A case report

Ryo Yano, Takuma Koga, Kenji Tsumura, Jun Sasaki et al.
Modern Rheumatology Case Reports
Drug-Induced Adverse Reactions
article

Development of a psoriasis-like eruption during treatment with mepolizumab: A case report

Ryo Yano, Takuma Koga, Kenji Tsumura, Jun Sasaki, Yo Kaku, Tomoaki Hoshino, Yoshihisa Tokunaga, Shinjiro Kaieda, Masanobu Matsuoka, Tomotaka Kawayama, Takashi Kinoshita
article en

Abstract

Mepolizumab is effective for treating eosinophilic granulomatosis with polyangiitis (EGPA), severe eosinophilic asthma (SEA), and chronic rhinosinusitis with nasal polyps (CRSwNP), but unexpected adverse events associated with anti-interleukin-5 (IL-5) monoclonal antibodies have not yet been fully characterized. Herein, we report the case of a 56-year-old woman who developed a psoriasis-like eruption ~18 months after starting subcutaneous mepolizumab (300 mg every 4 weeks) for EGPA, SEA, and CRSwNP. She had no personal or family history of psoriasis or atopic dermatitis. Small punctate erythematous lesions first appeared on the back, before gradually spreading to the trunk and extremities. Skin biopsy showed neutrophilic infiltration within the stratum corneum, focal hypogranulosis, dilated tortuous capillaries, and increased mitotic activity in the basal layer. Prominent regular elongation of the rete ridges was not evident. The overall clinicopathological findings supported a diagnosis of a psoriasis-like eruption, with no eosinophils being identified in either the epidermis or dermis. Topical treatment with calcipotriol and betamethasone, while mepolizumab was continued at the same dose, produced only temporary improvement followed by recurrence. The eruption improved following temporary mepolizumab discontinuation, but the patient’s asthma exacerbations recurred. The mepolizumab dose was therefore reduced to 100 mg every 4 weeks, and a potent topical corticosteroid was added. The eruption resolved within 3 months thereafter, without recurrence, and control of EGPA, SEA, and CRSwNP was maintained. Although the psoriasis-like eruption improved after mepolizumab dose reduction, the concurrent topical treatment intensification means this improvement cannot be attributed to the dose reduction alone.

Modern Rheumatology Case Reports
Kurume University (JP)
Drug-Induced Adverse Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon